ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2009 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Apr. 23, 2009-- ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, April 30, 2009 to discuss the Company’s financial results for the three-month period ended March 31, 2009 – the third quarter of ImmunoGen’s 2009 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through May 6, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen’s proprietary cell-killing agents specifically to cancer targets. In addition to the Company’s clinical pipeline, ImmunoGen collaborators Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and the naked antibody AVE1642 is in clinical trials through the Company’s collaboration with sanofi-aventis. The most advanced TAP compound, T-DM1, is in Phase III testing. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
Source: ImmunoGen, Inc.
ImmunoGen, Inc.
Carol Hausner
Executive Director, Investor Relations and Corporate Communications
Tel: 781-895-0600
info@immunogen.com
